Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines–Heart Failure Registry

American Heart Journal

Volumn 211, Issue , 2019, Pages 1-10

  Ziaeian, Boback ^a,b   Hernandez, Adrian F ^c,d   DeVore, Adam D ^c,d   Wu, Jingjing ^c   Xu, Haolin ^c   Heidenreich, Paul A ^e   Matsouaka, Roland A ^c,f   Bhatt, Deepak L ^g   Yancy, Clyde W ^h   Fonarow, Gregg C ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ALL CAUSE MORTALITY; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RISK; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VERY ELDERLY; CAUSE OF DEATH; COMORBIDITY; COMPLICATION; DIABETIC COMPLICATION; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROPORTIONAL HAZARDS MODEL; REGISTER; UNITED STATES;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; COMORBIDITY; DIABETES COMPLICATIONS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; PATIENT READMISSION; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; REGISTRIES; STROKE VOLUME; UNITED STATES;

EID: 85061981277     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2019.01.006     Document Type: Article

References (29)

1. Allen, L.A., Fonarow, G.C., Liang, L., et al. Medication initiation burden required to comply with heart failure guideline recommendations and hospital quality measures. Circulation [Internet] 132:14 (2015), 1347–1353 Available from: http://circ.ahajournals.org/lookup/doi/10.1161/CIRCULATIONAHA.115.014281.
2. Geiss, L.S., Wang, J., Cheng, Y.J., et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. Jama [Internet] 312:12 (2014), 1218–1226 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25247518.
3. Centers for Disease Control, Long-term trends in diabetes. Available from: http://www.cdc.gov/diabetes/data, 2016.
4. Ziaeian, B., Fonarow, G.C., Epidemiology and aetiology of heart failure. Nat Rev Cardiol [Internet] 13:6 (2016 Jun), 1–11 Available from: http://www.nature.com/doifinder/10.1038/nrcardio.2016.25.
5. Win, T.T., Davis, H.T., Laskey, W.K., Mortality among patients hospitalized with heart failure and diabetes mellitus. Circ Hear Fail [Internet], 9(5), 2016, e003023 Available from: http://circheartfailure.ahajournals.org/lookup/doi/10.1161/CIRCHEARTFAILURE.115.003023.
6. Echouffo-Tcheugui, J.B., Xu, H., DeVore, A.D., et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines–Heart Failure registry. Am Heart J [Internet] 182 (2016), 9–20, 10.1016/j.ahj.2016.07.025 [Available from:].
7. Sharma, A., Zhao, X., Hammill, B.G., et al. Trends in noncardiovascular comorbidities among patients hospitalized for heart failure. Circ Hear Fail [Internet], 11(6), 2018, e004646 Available from: http://circheartfailure.ahajournals.org/lookup/doi/10.1161/CIRCHEARTFAILURE.117.004646.
8. Boudina, S., Abel, E.D., Diabetic cardiomyopathy revisited. Circulation 115:25 (2007), 3213–3223.
9. Cavender, M.A., Steg, P.G., Smith, S.C., et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 132:10 (2015), 923–931.
10. Fonarow, G.C., Abraham, W.T., Albert, N.M., et al. Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): Rationale and design. Am Heart J 148:1 (2004), 43–51.
11. Smaha, L.A., The American Heart Association Get With the Guidelines Program. Am Heart J, 148(5 SUPPL), 2004.
12. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128 (2013), e240–e327.
13. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J [Internet] 37:27 (2016), 2129–2200 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27207191.
14. Cheng, R.K., Cox, M., Neely, M.L., et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J [Internet] 168:5 (2014), 721–730.e3 [cited 2015 Jan 19;Available from] http://www.ncbi.nlm.nih.gov/pubmed/25440801.
15. Vivo, R.P., Krim, S.R., Liang, L., et al. Short- and long-term rehospitalization and mortality for heart failure in 4 racial/ethnic populations. J Am Heart Assoc [Internet], 3(5), 2014, e001134 Available from: http://jaha.ahajournals.org/cgi/doi/10.1161/JAHA.114.001134.
16. Eapen, Z.J., McCoy, L.A., Fonarow, G.C., et al. Utility of socioeconomic status in predicting 30-day outcomes after heart failure hospitalization. Circ Heart Fail 8:3 (2015), 473–480.
17. Greenberg, B.H., Abraham, W.T., Albert, N.M., et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 154:4 (2007), 647–654.
18. Kristensen, S.L., Preiss, D., Jhund, P.S., et al. Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9:1 (2016), 1–12.
19. Deedwania, P.C., Ahmed, M.I., Feller, M.A., et al. Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Eur J Heart Fail 13:5 (2011), 551–559.
20. Paulus, W.J., Tschöpe, C., A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62:4 (2013), 263–271.
21. Mentz, R.J., Kelly, J.P., Von Lueder, T.G., et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64:21 (2014), 2281–2293.
22. MacDonald, M.R., Petrie, M.C., Varyani, F., et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure—an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:11 (2008), 1377–1385.
23. Kristensen, S.L., Mogensen, U.M., Jhund, P.S., et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection). Circulation [Internet] 135:8 (2017), 724–735 Available from http://www.ncbi.nlm.nih.gov/pubmed/28052977.
24. Sandesara, P.B., O'Neal, W.T., Kelli, H.M., et al. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care 41:1 (2018), 150–155.
25. Tribouilloy, C., Rusinaru, D., Mahjoub, H., et al. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study. Heart [Internet] 94:11 (2008), 1450–1455 Available from: http://heart.bmj.com/cgi/doi/10.1136/hrt.2007.128769.
26. Solomon, S.D., Rizkala, A.R., Gong, J., et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail 5:7 (2017), 471–482.
27. Lehrke, M., Marx, N., Diabetes Mellitus and Heart Failure. Am J Cardiol 120:1 (2017), S37–S47.
28. Dei Cas, A., Khan, S.S., Butler, J., et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 3:2 (2015), 136–145.
29. Fitchett, D., Zinman, B., Wanner, C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 37:19 (2016), 1526–1534.